American Century Companies Inc. Makes New Investment in Zymeworks Inc. (NYSE:ZYME)

American Century Companies Inc. bought a new stake in Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 39,942 shares of the company's stock, valued at approximately $585,000. American Century Companies Inc. owned approximately 0.06% of Zymeworks as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ZYME. Barclays PLC boosted its stake in Zymeworks by 476.3% in the third quarter. Barclays PLC now owns 154,384 shares of the company's stock valued at $1,937,000 after acquiring an additional 127,595 shares during the last quarter. State Street Corp lifted its stake in Zymeworks by 6.1% in the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock valued at $14,706,000 after purchasing an additional 67,401 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Zymeworks by 93.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after buying an additional 311,107 shares during the last quarter. FMR LLC increased its position in Zymeworks by 84.2% in the third quarter. FMR LLC now owns 3,336 shares of the company's stock worth $42,000 after buying an additional 1,525 shares during the last quarter. Finally, Stifel Financial Corp lifted its position in shares of Zymeworks by 2.1% during the 3rd quarter. Stifel Financial Corp now owns 73,654 shares of the company's stock valued at $924,000 after buying an additional 1,540 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZYME has been the topic of a number of research reports. Lifesci Capital began coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price objective on the stock. HC Wainwright boosted their price target on shares of Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Monday, March 10th. Citigroup upped their price target on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, March 7th. Finally, Wells Fargo & Company lifted their price objective on shares of Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $21.00.

Insider Activity

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 320,690 shares of Zymeworks stock in a transaction on Tuesday, March 11th. The shares were acquired at an average cost of $11.49 per share, for a total transaction of $3,684,728.10. Following the completion of the transaction, the director now directly owns 16,040,851 shares of the company's stock, valued at approximately $184,309,377.99. The trade was a 2.04 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In the last three months, insiders have bought 1,296,142 shares of company stock worth $15,586,088. 1.92% of the stock is currently owned by insiders.

Zymeworks Stock Up 1.3 %

NYSE:ZYME traded up $0.14 during midday trading on Thursday, hitting $11.39. The company had a trading volume of 72,957 shares, compared to its average volume of 619,518. The company has a market capitalization of $792.55 million, a PE ratio of -7.58 and a beta of 1.18. Zymeworks Inc. has a 52-week low of $7.97 and a 52-week high of $17.70. The stock's fifty day moving average price is $12.46 and its 200-day moving average price is $13.53.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.